GNMLF (Genomma Lab InternacionalB de CV) ROE % Adjusted to Book Value : 7.50% (As of Dec. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Genomma Lab InternacionalB de CV ROE % Adjusted to Book Value?

Genomma Lab InternacionalB de CV's ROE % for the quarter that ended in Dec. 2024 was 16.19%. Genomma Lab InternacionalB de CV's PB Ratio for the quarter that ended in Dec. 2024 was 2.16. Genomma Lab InternacionalB de CV's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was 7.50%.

Genomma Lab InternacionalB de CV ROE % Adjusted to Book Value Historical Data

The historical data trend for Genomma Lab InternacionalB de CV's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomma Lab InternacionalB de CV ROE % Adjusted to Book Value Chart

Genomma Lab InternacionalB de CV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

7.77

6.37

9.09

8.30

8.53

Genomma Lab InternacionalB de CV Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-1.73	9.79	14.78	12.41	7.50

Competitive Comparison of Genomma Lab InternacionalB de CV's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genomma Lab InternacionalB de CV's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's ROE % Adjusted to Book Value falls into.

Genomma Lab InternacionalB de CV ROE % Adjusted to Book Value Calculation

Genomma Lab InternacionalB de CV's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	18.43%	/	2.16
	=	8.53%

Genomma Lab InternacionalB de CV's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	16.19%	/	2.16
	=	7.50%

Genomma Lab InternacionalB de CV ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Genomma Lab InternacionalB de CV's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Genomma Lab InternacionalB de CV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genomma Lab Internacional SAB de CV (OTCPK:GNMLF) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

LABB:Mexico GEKA:Germany

Address

Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210

Website

https://www.genommalab.com

Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.